Daniell Richard 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Dec 11, 2025

Form 4

Period: 2025-12-09

Exec. VP, European Commercial

Transactions

Exercise/Conversion
Ordinary Shares
2025-12-09$18.61/sh+100,457$1,869,505→ 148,841 total
Exercise/Conversion
Ordinary Shares
2025-12-09$16.99/sh+15,011$255,037→ 163,852 total
Sale
Ordinary Shares
2025-12-09$28.68/sh−115,468$3,311,126→ 48,384 total
Exercise/Conversion
Stock Options (right to buy)
2025-12-09−100,457→ 0 total
Exercise: $18.61Exp: 2028-02-09→ Ordinary Shares (100,457 underlying)
Exercise/Conversion
Stock Options (right to buy)
2025-12-09−15,011→ 0 total
Exercise: $16.99Exp: 2027-09-18→ Ordinary Shares (15,011 underlying)

Footnotes (4)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.635 to $28.765, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F3]Stock options were granted on February 9, 2018, with 33,485 vested on each of February 9, 2020 and February 9, 2021, and 33,487 vested on February 9, 2022.
[F4]Stock options were granted on September 18, 2017, with 7,505 vested on September 18, 2018, and 7,506 vested on September 18, 2019.

Documents

1 file